Ticagrelor presentation blood medicine munib.pptx

anticauglant ticargrelor blood thinner

1. Ticagrelor clinical trials Werrick Pharmaceuticals

2. PLATO Trial Ticagrelor vs Clopidogrel Primary Outcomes Vascular mortality, MI, or CVA 9.8% vs. 11.7% Major bleeding (study criteria) 11.6% vs. 11.2% Secondary Outcomes All-cause mortality, MI, or CVA 10.2% vs. 12.3% Vascular mortality, MI, stroke, recurrent severe ischemia, recurrent ischemia, TIA, or other arterial thrombotic event 14.6% vs. 16.7% Conclusion In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding

3. PEGASUS-TIMI 54 trial safety and effectiveness of the long-term use of ticagrelor in patients with coronary artery disease (CAD) Conclusion Long-term dual antiplatelet therapy with low-dose aspirin and ticagrelor should be considered in appropriate patients with a myocardial infarction

4. TWILIGHT trial A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention Conclusion The trial's findings suggest that shortened durations of DAPT followed by ticagrelor monotherapy could be a safe and effective strategy for patients who have undergone PCI with DES and are at high risk for ischemic and bleeding events